The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Rare ALK: Clinical characteristics and efficacy of targeted therapy in NSCLC with ALK fusions other than EML4::ALK.
 
Felix Carl Saalfeld
Honoraria - Accord Healthcare; AstraZeneca; CME Education Resources; GWT; Janssen; Novartis; Pfizer; Pfizer; Roche; Takeda; Thieme
Consulting or Advisory Role - AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; Janssen; Janssen; MSD; Pfizer; Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Janssen; Lilly; Roche; Takeda
 
Marie-Elisabeth Leßmann
Honoraria - AstraZeneca
 
Lea Ruge
Honoraria - Johnson & Johnson/Janssen
Consulting or Advisory Role - Amgen
Travel, Accommodations, Expenses - Amgen
 
Oliver Illini
Honoraria - Boehringer Ingelheim; Bristol Myers Squibb Foundation; Johnsion&Johnson; Lilly; Merck Sharp & Dohme; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Johnsion&Johnson; Lilly; Merck Sharp & Dohme; Pfizer; Roche
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Menarini; Merck Sharp & Dohme; Pfizer; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Pfizer; Roche
 
Diego Kauffmann-Guerrero
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; MSD; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Boehringer Ingelheim; Daiichi Sankyo
Research Funding - Gilead Sciences
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Janssen; Pfizer; Takeda
 
Kaija Minuth-Fuchs
Honoraria - AstraZeneca
 
Achim Rittmeyer
Consulting or Advisory Role - AbbVie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Daichi Sankyo; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Roche/Genentech
 
Isabell Goetting
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Katharina Schildknecht
No Relationships to Disclose
 
Bastian Eul
Honoraria - AstraZeneca
Consulting or Advisory Role - Sanofi
 
Christoph Schubart
Honoraria - AstraZeneca
 
Sacha Rothschild
Honoraria - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); PharmaMar (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Takeda (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); PharmaMar (Inst); Roche Pharma AG (Inst); Takeda (Inst)
Speakers' Bureau - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Roche Pharma AG (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Roche Pharma AG (Inst); Sanofi; Takeda (Inst)
Other Relationship - Federal Drug Commission of the Swiss Federal Office of Public Health; Swiss Group for Clinical Cancer Research (SAKK) (Inst)
 
Christian Grohé
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Merck Sharp & Dohme; Novartis; Pfizer; Roche
 
Karin Armster
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb; MSD; Roche; Takeda
 
Mohorcic Katja
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Takeda
 
Tobias Overbeck
Consulting or Advisory Role - AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; Daiichi Sankyo Europe GmbH; Johnson & Johnson/Janssen; Merck KGaA; Pfizer; Pierre Fabre; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH
 
Cornelius Waller
Honoraria - Alvotech; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck; Merck Sharp & Dohme; Mylan/Viatris; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Alvotech; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai/Roche; Lilly; Merck; MSD; Mylan/Viatris; Novartis/Ipsen; Pfizer; Roche; Takeda; Vifor Pharma
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; Lilly
 
Rita Vesce
No Relationships to Disclose
 
Petros Christopoulos
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Merck Serono; Novartis; Pfizer; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); Roche (Inst); Takeda (Inst)
 
Martin Wermke
Honoraria - Amgen; BMS GmbH & Co. KG; Boehringer Ingelheim; GWT; Janssen; Lilly; Merck Serono; Merck Serono; Novartis; Pfizer; SYNLAB
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; ImCheck therapeutics; immatics; ISA Pharmaceuticals; Lilly; Novartis; PharmaMar; Regeneron; Tacalyx; Zymeworks
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; GEMoaB; immatics; Iovance Biotherapeutics; Janssen Oncology; Merck Serono; Pfizer; Sanofi/Aventis
 
National Network Genomic Medicine Lung Cancer (nNGM)
No Relationships to Disclose